Form 4 for EW Edwards Lifesciences
Accepted 2022-05-05 00:00:00 ET · period of report 2022-05-03 · accession 0001225208-22-006584 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-05-05 | 2022-05-04 | EW | Szyman Catherine M. | CVP, Critical Care | S - Sale+OE | $104.87 | -23.4K | 30.9K | -43% | -$2.45M |
| D | 2022-05-05 | 2022-05-04 | EW | Szyman Catherine M. | CVP, Critical Care | F - Tax | $105.93 | -493 | 54.3K | -0.9% | -$52.2K |
| D | 2022-05-05 | 2022-05-03 | EW | Szyman Catherine M. | CVP, Critical Care | A - Grant | $0.00 | +3,775 | 31.3K | +14% | $0 |
| D | 2022-05-05 | 2022-05-04 | EW | Szyman Catherine M. | CVP, Critical Care | M - OptEx | $21.76 | +23.4K | 54.7K | +75% | +$509.2K |
| DM | 2022-05-05 | 2022-05-03 | EW | Szyman Catherine M. | CVP, Critical Care | A - Grant | $0.00 | +35.3K | 4,725 | New | $0 |
| D | 2022-05-05 | 2022-05-04 | EW | Szyman Catherine M. | CVP, Critical Care | M - OptEx | $0.00 | -23.4K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-04 | S | D | 3,796 | $105.88 | 50,454.66 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $105.77 to $105.92. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2022-05-04 | S | D | 9,155 | $104.18 | 41,299.66 | D | — | — | (F4) This transaction was executed in multiple trades at prices ranging from $103.77 to $104.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2022-05-04 | F | D | 493 | $105.93 | 54,250.66 | D | — | — | |
| 4 | Common | Common Stock | 2022-05-04 | S | D | 10,449 | $105.10 | 30,850.66 | D | — | — | (F5) This transaction was executed in multiple trades at prices ranging from $104.77 to $105.74. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 5 | Common | Common Stock | 2022-05-03 | A | A | 3,775 | $0.00 | 31,343.66 | D | — | — | (F1) These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |
| 6 | Common | Common Stock | 2022-05-04 | M | A | 23,400 | $21.76 | 54,743.66 | D | — | — | |
| 7 | Derivative | Employee Stock Option (Right to Acquire) | 2022-05-03 | A | A | 30,600 | $0.00 | 30,600 | D | $105.93 · 2023-05-03 to 2029-05-02 | 30,600 Common Stock | (F6) These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |
| 8 | Derivative | Employee Stock Option (Right to Acquire) | 2022-05-04 | M | D | 23,400 | $0.00 | 0 | D | $21.76 · 2016-05-14 to 2022-05-13 | 23,400 Common Stock | |
| 9 | Derivative | Performance Rights | 2022-05-03 | A | A | 4,725 | $0.00 | 4,725 | D | — · 2025-05-03 to — | 4,725 Common Stock | (F7) Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. |